SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$36.12 USD
-0.08 (-0.22%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $36.16 +0.04 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
SpringWorks Therapeutics [SWTX]
Reports for Purchase
Showing records 121 - 140 ( 190 total )
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Polymorph Patent Extends Commercial Window to 2041; Raising PT to $136
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Mirdametinib Favorable Neurofibromatosis Safety Profile Persists; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Sixth Nirogacestat Collaboration Agreement Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
In-Licensed TEAD Inhibitor Targets Large Market; 1Q21 Financials; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
1Q21 Financials; It?s TEA Time with New TEAD Platform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
SWTX Sees Negligible Risks Due to Elranatamab?s AEs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Incrementally Positive Interim Results for Mirdametinib in NF-1 PN; 2020 Financials Reported; Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
ICER Indicates BLENREP OS Benefit and Cost-Effectiveness; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Edging Closer to First Commercial Launches; Raising PT to $101
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Potentially Pivotal Year in 2021; Raising PT to $87
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R